Candel Therapeutics, Inc.
CADLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Candel Therapeutics, Inc. (CADL) is listed under Biotechnology. Valued at $592.8M, CADL is a small-cap name in its sector. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Market Cap
$592.8M
Beta
-0.58
P/E (TTM)
—
P/E (Fwd)
36.77
EPS (TTM)
$-1.01
EPS (Fwd)
$0.22
ROE
-51.2%
ROA
-23.6%
Cash
$194.8M
Total Debt
$49.3M
Free CF
-$37.9M
52W Change
48.4%
Annual Financials
Cash vs Debt
Candel Therapeutics, Inc. holds $194.8M in cash against $49.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$37.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -51.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $125K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Candel Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, CADL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CADL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.